The prognostic value of miR-34a expression in completely resected gastric cancer: Tumor recurrence and overall survival

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 2, 2015, Pages 2635-2641

  Zhang, Huaping ^a   Li, Shaojun ^a   Yang, Junqi ^b   Liu, Shuai ^b   Gong, Xiangqian ^a   Yu, Xiaofeng ^a  

^a YANTAI YUHUANGDING HOSPITAL   (China)

^b QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Gastric cancer; MicroRNA 34a; Overall survival; Tumor recurrence

Indexed keywords

CAPECITABINE; CARBOHYDRATE ANTIGEN; CARCINOEMBRYONIC ANTIGEN; MICRORNA 34A; OXALIPLATIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; FEMALE; GASTRECTOMY; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CANCER; TUMOR DIFFERENTIATION; TUMOR VOLUME;

EID: 84926359159     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. [1] World Health Organization: Globocan 2012 Stomach Cancer: Estimated Incidence, Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr/old/FactSheets/cancers/stomach-new.asp. Accessed October 14, 2014.
2. [2] Orditura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Laterza MM, Andreozzi F, Ventriglia J, Savastano B, Mabilia A, Lieto E, Ciardiello F and De Vita F. Treatment of gastric cancer. World J Gastroenterol 2014; 20: 1635-1649.
3. [3] Ambros V. The functions of animal microRNAs. Nature 2004; 431: 350-355.
4. [4] Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
5. [5] Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, Singh S, Cheng CL, Yu CJ, Lee YC, Chen HS, Su TJ, Chiang CC, Li HN, Hong QS, Su HY, Chen CC, Chen WJ, Liu CC, Chan WK, Chen WJ, Li KC, Chen JJ and Yang PC. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008; 13: 48-57.
6. [6] He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ and Hammond SM. A microRNA polycistron as a potential human oncogene. Nature 2005; 435: 828-833.
7. [7] Voorhoeve PM, le Sage C, Schrier M, Gillis AJ, Stoop H, Nagel R, Liu YP, van Duijse J, Drost J, Griekspoor A, Zlotorynski E, Yabuta N, De Vita G, Nojima H, Looijenga LH and Agami R. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 2006; 124: 1169-1181.
8. [8] Osawa S, Shimada Y, Sekine S, Okumura T, Nagata T, Fukuoka J and Tsukada K. MicroRNA profiling of gastric cancer patients from formalin-fixed paraffin-embedded samples. Oncol Lett 2011; 2: 613-619.
9. [9] Wang AM, Huang TT, Hsu KW, Huang KH, Fang WL, Yang MH, Lo SS, Chi CW, Lin JJ and Yeh TS. Yin Yang 1 is a target of microRNA-34 family and contributes to gastric carcinogenesis. Oncotarget 2014; 5: 5002-5016.
10. [10] Cha YH, Kim NH, Park C, Lee I, Kim HS and Yook JI. MiRNA-34 intrinsically links p53 tumor suppressor and Wnt signaling. Cell Cycle 2012; 11: 1273-1281.
11. [11] Ji Q, Hao X, Meng Y, Zhang M, Desano J, Fan D and Xu L. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 2008; 8: 266.
12. [12] Cao W, Fan R, Wang L, Cheng S, Li H, Jiang J, Geng M, Jin Y and Wu Y. Expression and regulatory function of miRNA-34a in targeting survivin in gastric cancer cells. Tumour Biol 2013; 34: 963-971.
13. [13] Cao W, Yang W, Fan R, Li H, Jiang J, Geng M, Jin Y and Wu Y. miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway. Tumour Biol 2014; 35: 1287-1295.
14. [14] Peng Y, Guo JJ, Liu YM and Wu XL. MicroRNA-34A inhibits the growth, invasion and metastasis of gastric cancer by targeting PDGFR and MET expression. Biosci Rep 2014; 34: e00112.
15. [15] Yao Y, Suo AL, Li ZF, Liu LY, Tian T, Ni L, Zhang WG, Nan KJ, Song TS and Huang C. MicroRNA profiling of human gastric cancer. Mol Med Rep 2009; 2: 963-970.
16. [16] Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, Bentwich Z and Oren M. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007; 26: 731-743.
17. [17] Bader AG. miR-34-a microRNA replacement therapy is headed to the clinic. Front Genet 2012; 3: 120.
18. [18] Balca-Silva J, Sousa Neves S, Goncalves AC, Abrantes AM, Casalta-Lopes J, Botelho MF, Sarmento-Ribeiro AB and Silva HC. Effect of miR-34b overexpression on the radiosensitivity of non-small cell lung cancer cell lines. Anticancer Res 2012; 32: 1603-1609.
19. [19] Stanitz E, Juhasz K, Toth C, Gombos K, Natali PG and Ember I. Evaluation of MicroRNA expression pattern of gastric adenocarcinoma associated with socioeconomic, environmental and lifestyle factors in northwestern Hungary. Anticancer Res 2013; 33: 3195-3200.
20. [20] Agostini M and Knight RA. miR-34: from bench to bedside. Oncotarget 2014; 5: 872-881.
21. [21] Zhao G, Guo J, Li D, Jia C, Yin W, Sun R, Lv Z and Cong X. MicroRNA-34a suppresses cell proliferation by targeting LMTK3 in human breast cancer mcf-7 cell line. DNA Cell Biol 2013; 32: 699-707.
22. [22] Ma Y, Bao-Han W, Lv X, Su Y, Zhao X, Yin Y, Zhang X, Zhou Z, MacNaughton WK and Wang H. MicroRNA-34a mediates the autocrine signaling of PAR2-activating proteinase and its role in colonic cancer cell proliferation. PLoS One 2013; 8: e72383.
23. [23] Xia J, Duan Q, Ahmad A, Bao B, Banerjee S, Shi Y, Ma J, Geng J, Chen Z, Rahman KM, Miele L, Sarkar FH and Wang Z. Genistein inhibits cell growth and induces apoptosis through up-regulation of miR-34a in pancreatic cancer cells. Curr Drug Targets 2012; 13: 1750-1756.